2wc0 Citations

Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme.

J Biol Chem 284 14177-88 (2009)
Cited: 52 times
EuropePMC logo PMID: 19321446

Abstract

Insulin is a hormone vital for glucose homeostasis, and insulin-degrading enzyme (IDE) plays a key role in its clearance. IDE exhibits a remarkable specificity to degrade insulin without breaking the disulfide bonds that hold the insulin A and B chains together. Using Fourier transform ion cyclotron resonance (FTICR) mass spectrometry to obtain high mass accuracy, and electron capture dissociation (ECD) to selectively break the disulfide bonds in gas phase fragmentation, we determined the cleavage sites and composition of human insulin fragments generated by human IDE. Our time-dependent analysis of IDE-digested insulin fragments reveals that IDE is highly processive in its initial cleavage at the middle of both the insulin A and B chains. This ensures that IDE effectively splits insulin into inactive N- and C-terminal halves without breaking the disulfide bonds. To understand the molecular basis of the recognition and unfolding of insulin by IDE, we determined a 2.6-A resolution insulin-bound IDE structure. Our structure reveals that IDE forms an enclosed catalytic chamber that completely engulfs and intimately interacts with a partially unfolded insulin molecule. This structure also highlights how the unique size, shape, charge distribution, and exosite of the IDE catalytic chamber contribute to its high affinity ( approximately 100 nm) for insulin. In addition, this structure shows how IDE utilizes the interaction of its exosite with the N terminus of the insulin A chain as well as other properties of the catalytic chamber to guide the unfolding of insulin and allowing for the processive cleavages.

Articles - 2wc0 mentioned but not cited (1)

  1. Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ. J Biol Chem 284 14177-14188 (2009)


Reviews citing this publication (7)

  1. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus. Tang WJ. Trends Endocrinol Metab 27 24-34 (2016)
  2. Multiple functions of insulin-degrading enzyme: a metabolic crosslight? Tundo GR, Sbardella D, Ciaccio C, Grasso G, Gioia M, Coletta A, Polticelli F, Di Pierro D, Milardi D, Van Endert P, Marini S, Coletta M. Crit Rev Biochem Mol Biol 52 554-582 (2017)
  3. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. Jha NK, Jha SK, Kumar D, Kejriwal N, Sharma R, Ambasta RK, Kumar P. J Alzheimers Dis 48 891-917 (2015)
  4. Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme. González-Casimiro CM, Merino B, Casanueva-Álvarez E, Postigo-Casado T, Cámara-Torres P, Fernández-Díaz CM, Leissring MA, Cózar-Castellano I, Perdomo G. Biomedicines 9 86 (2021)
  5. Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Wei Z, Koya J, Reznik SE. Front Neurosci 15 687157 (2021)
  6. Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer? Lesire L, Leroux F, Deprez-Poulain R, Deprez B. Cells 11 1228 (2022)
  7. Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review. Azam MS, Wahiduzzaman M, Reyad-Ul-Ferdous M, Islam MN, Roy M. Pharm Res 39 611-629 (2022)

Articles citing this publication (44)